{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:54:18Z","timestamp":1783652058563,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-03979-7","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T17:49:21Z","timestamp":1740419361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The impact of asymptomatic kidney stones on disease progression in autosomal dominant polycystic kidney disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Omer Celal","family":"Elcioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyza","family":"Yatci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak Baris","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safak","family":"Mirioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Gursu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumeyza","family":"Kazancioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"9569","key":"3979_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal Dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(07)60601-1.","journal-title":"Lancet"},{"issue":"3","key":"3979_CR2","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall E, Audr\u00e9zet MP, Rousseau A, Hourmant M, Renaudineau E, Charase C, et al. The PROPKD score: a New Algorithm to predict renal survival in autosomal Dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942\u201351.","journal-title":"J Am Soc Nephrol"},{"key":"3979_CR3","unstructured":"Harris PC, Torres VE. Polycystic Kidney Disease, Autosomal Dominant. GeneReviews\u00ae. University of Washington; 2022. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1246\/"},{"issue":"1","key":"3979_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00345-024-05348-9","volume":"43","author":"SJM Stoots","year":"2024","unstructured":"Stoots SJM, Somani BK, Durutovic O, Cavadas V, Secker A, Jung HU, et al. Kidney stone analysis: EAU Section of Urolithiasis Survey on Current practices and perspectives Worldwide. World J Urol. 2024;43(1):21\u20139. https:\/\/doi.org\/10.1007\/s00345-024-05348-9.","journal-title":"World J Urol"},{"issue":"12","key":"3979_CR5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/ndt\/gfz281","volume":"35","author":"Y Pei","year":"2020","unstructured":"Pei Y, Kalatharan V, Grewal G, Nash DM, Garg AX, Welk B, et al. Stone Prevalence in ADPKD: a systematic review and Meta-analysis. Nephrol Dial Transpl. 2020;35(12):2073\u201383. https:\/\/doi.org\/10.1093\/ndt\/gfz281.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"3979_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Torres VE, et al. Autosomal Dominant polycystic kidney disease: KDIGO Summary. Kidney Int. 2015;88(1):17\u201327. https:\/\/doi.org\/10.1038\/ki.2015.59.","journal-title":"Kidney Int"},{"issue":"4","key":"3979_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0272-6386(88)80071-5","volume":"11","author":"VE Torres","year":"1988","unstructured":"Torres VE, Erickson SB, Smith LH, Harmon AJ, Harrison BJ, Holley KE, et al. The Association of Nephrolithiasis and ADPKD. Am J Kidney Dis. 1988;11(4):318\u201325. https:\/\/doi.org\/10.1016\/S0272-6386(88)80071-5.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3979_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"RU M\u00fcller","year":"2022","unstructured":"M\u00fcller RU, Messchendorp AL, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O, et al. An update on the Use of Tolvaptan for ADPKD. Nephrol Dial Transpl. 2022;37(5):825\u201339. https:\/\/doi.org\/10.1093\/ndt\/gfab312.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"3979_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Devuyst O, et al. Recommendations for the Use of Tolvaptan in autosomal Dominant polycystic kidney disease: a position Statement on Behalf of the ERA-EDTA Working Group on Inherited Kidney Disorders. Nephrol Dial Transpl. 2016;31(3):337\u201348. https:\/\/doi.org\/10.1093\/ndt\/gfv456.","journal-title":"Nephrol Dial Transpl"},{"issue":"19","key":"3979_CR10","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y. New creatinine- and cystatin C\u2013based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"issue":"4","key":"3979_CR11","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s10157-023-02378-2","volume":"27","author":"O Chasan","year":"2023","unstructured":"Chasan O, Mirioglu S, Artan AS, Gursu M, Kazancioglu R, Elcioglu OC. Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study. Clin Exp Nephrol. 2023;27(4):912\u20138.","journal-title":"Clin Exp Nephrol"},{"issue":"20","key":"3979_CR12","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354(20):2122\u201330. https:\/\/doi.org\/10.1056\/NEJMoa054341.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-03979-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-03979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T17:49:22Z","timestamp":1740419362000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-03979-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3979"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-03979-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was in accordance with the ethical principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Conference on Harmonization, and local regulatory requirements. The study was approved by the Bezmialem Vakif University Ethics Committee with the approval\/date and number: 13 March, 2024, 2024\/19-E-54022451-050.04-146750. Informed consent was waived by the Bezmialem Vakif University Ethics Committee due to the retrospective nature of the study, in accordance with national regulations (Decision No: 2024\/19-E-54022451-050.04-146750).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}